Jesus Quintero, MD
Nephrology · Ft Lauderdale, FLNPI 1902856438
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Amgen at 26.1% of the total. Reporting peaked in 2022 at $267 and has fallen 89.9% since, to $27 in 2025. That places this record below the midpoint for nephrology clinicians in FL, where the typical reported total is $1,407.
Across 42 payments — averaging $21.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$240
- AstraZeneca$206
- Mallinckrodt Hospital Products Inc.$152
- Calliditas Therapeutics US Inc.$86
- Aurinia Pharma U.S., Inc.$53
- Bayer$48
- plus $133 from 4 others
What the payments were for
- Food & beverage$87495%
- Education$445%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 12 | $240 |
| AstraZeneca | 10 | $206 |
| Mallinckrodt Hospital Products Inc. | 5 | $152 |
| Calliditas Therapeutics US Inc. | 4 | $86 |
| Aurinia Pharma U.S., Inc. | 3 | $53 |
| Bayer | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| Akebia Therapeutics Inc | 2 | $45 |
| Fresenius USA Marketing, Inc. | 1 | $22 |
| GSK | 1 | $20 |
How this compares
$918 in reported general payments places this provider in the 40th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 20 | $5,004 |
| ProsolParenteral Amino Acid 20% No.1 | 22 | $3,977 |
| Bumetanide | 28 | $924 |
| Nifedipine ErNifedipine | 17 | $511 |
| Calcitriol | 14 | $330 |
| Hydralazine Hcl | 15 | $210 |
| Lisinopril | 35 | $183 |
| Carvedilol | 16 | $115 |
| Losartan Potassium | 22 | $115 |
| Furosemide | 39 | $88 |
| Hydrochlorothiazide | 11 | $63 |
| Tamsulosin Hcl | 12 | $44 |
| Amlodipine Besylate | 23 | $41 |
| Allopurinol | 15 | $22 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Ft Lauderdale
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
- Rafael Baez BonillaFort Lauderdale$175K
- Gabriel ContrerasMiami$133K
- Fouad ChebibJacksonville$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.